The following table provides the Company's unbilled receivables and deferred revenues from contracts with customers:


(In millions)	July 3, 2020		September 27, 2019
Unbilled receivables - current	$	320.1	$	346.7
Unbilled receivables - long-term ⁽¹⁾	72.1		35.1


Deferred revenues - current	(778.4)		(766.0)
Deferred revenues - long-term ⁽²⁾	(70.8)		(73.1)
Total net unbilled receivables (deferred revenues)	$	(457.0)	$	(457.3)

⁽²⁾Included in other long-term liabilities on the Company's Condensed Consolidated Balance Sheets.

During the nine months ended July 3, 2020, unbilled receivables increased by $10.4 million, primarily due to the timing of billings in Oncology Systems, and deferred revenues increased by $10.1 million, primarily due to the contractual timing of billings occurring before the revenues were recognized.

During the three months and nine months ended July 3, 2020, the Company recognized revenues of $109.7 million and $586.6 million, respectively, which were included in the deferred revenues balances at September 27, 2019. During the three and nine

months ended June 28, 2019, the Company recognized revenues of $113.9 million and $545.1 million, respectively, which were included in the deferred revenues balances at September 28, 2018.

The following table represents the Company's unfulfilled performance obligations as of July 3, 2020, and the estimated revenues expected to be recognized in the future related to these unfulfilled performance obligations:


	Fiscal Years of Revenue Recognition
(In millions)	Remainder of 2020		2021		2022		Thereafter
Unfulfilled Performance Obligations	$	509.3	$	2,434.5	$	1,182.8	$	2,574.2

The table above includes both product and service unfulfilled performance obligations, which includes a component of service performance obligations that has not been invoiced. The fiscal years presented reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements and availability of products or customer acceptance terms.


(In millions)	July 3, 2020		September 27, 2019
Cash and cash equivalents	$	769.2	$	531.4
Restricted cash - current ⁽¹⁾	10.4		4.2
Restricted cash - long-term ⁽²⁾	10.9		8.5
Total cash, cash equivalents, and restricted cash	$	790.5	$	544.1

⁽¹⁾Included in prepaid expenses and other current assets on the Company's Condensed Consolidated Balance Sheets.


(In millions)	July 3, 2020		September 27, 2019

Raw materials and parts	$	372.7	$	376.5
Work-in-process	81.0		71.8
Finished goods	146.7		103.2
Total inventories	$	600.4	$	551.5


(In millions)	July 3, 2020		September 27, 2019
Income taxes payable	$	164.8	$	180.3

Deferred income taxes	83.4		75.3
Deferred revenues	70.8		73.1

Contingent consideration	27.7		42.3
Defined benefit pension plan	28.2		31.1
Other	42.4		38.0
Total other long-term liabilities	$	417.3	$	440.1


	Three Months Ended						Nine Months Ended
(In millions)	July 3, 2020		June 28, 2019		July 3, 2020		June 28, 2019
Gain on equity investments	$	25.7	$	2.0	$	27.1	$	23.8

Net foreign currency exchange gain (loss)	(1.2)		1.8		(0.2)		2.6
Other, net	0.6		0.4		1.7		1.0
Total other income, net	$	25.1	$	4.2	$	28.6	$	27.4